International Edition
Latest News
Business

SoCal Man Charged in $270 Million Medi-Cal Fraud Scheme

Orange County Man Pleads Guilty in $270 Million Medi-Cal Fraud Scheme A massive healthcare fraud operation in Southern California has come to a halt after Paul Richard Randall, a 66-year-old man from Orange, pleaded guilty to orchestrating a…

SoCal Man Charged in $270 Million Medi-Cal Fraud Scheme

Orange County Man Pleads Guilty in $270 Million Medi-Cal Fraud Scheme

A massive healthcare fraud operation in Southern California has come to a halt after Paul Richard Randall, a 66-year-old man from Orange, pleaded guilty to orchestrating a scheme that submitted nearly $270 million in fraudulent claims to Medi-Cal. Over an 11-month period, Randall and his accomplices exploited systemic loopholes to bill the state for expensive prescription drugs that were either medically unnecessary or never delivered to patients.

The Department of Justice described the operation as a brazen attack on taxpayer-funded benefit programs. First Assistant U.S. Attorney Bill Essayli noted that Randall essentially used the public health program as his “personal piggy bank.”

Exploiting the System: The Prior Authorization Loophole

The success of the fraud relied on a specific window of vulnerability within Medi-Cal’s operations. During a transition to a new payment system, Medi-Cal suspended its “prior authorization” requirement. Normally, this requirement forces healthcare providers to obtain approval before dispensing certain high-cost medications to ensure they are medically necessary before the state agrees to reimburse the provider.

Randall, along with co-schemers Kyrollos Mekail, 37, of Moreno Valley, and Patricia Anderson, 58, of West Hills, took advantage of this suspension. Operating through a business called Monte Vista Pharmacy, the group billed Medi-Cal tens of millions of dollars per month for high-reimbursement, non-contracted generic drugs.

The Mechanics of the Fraud

Between May 2022 and April 2023, Monte Vista Pharmacy billed Medi-Cal more than $269 million for 19 different non-contracted drugs. These medications contained low-cost generic ingredients and were frequently not dispensed to the purported recipients. In some instances, the pharmacy billed for Folite tablets—a vitamin available over the counter—as if they were expensive prescription pain medications.

The Mechanics of the Fraud

The financial impact of the scheme was staggering:

  • Total Billed: Over $269 million
  • Total Paid Out: More than $178 million
  • Duration: 11 months

Legal Consequences and Prosecution

Paul Richard Randall has been in custody since June 2025. He pleaded guilty to one count of wire fraud committed whereas on release. According to court documents, he also faced a felony count of health care fraud, which carries a potential penalty of up to 10 years in federal prison.

Assistant Attorney General A. Tysen Duva of the Justice Department’s Criminal Division emphasized that the government will aggressively prosecute those who exploit Medicaid. Duva characterized Randall as a “repeat fraudster” who stole public funds intended to help those in need.

Key Takeaways of the Case

Case Summary:

  • Primary Defendant: Paul Richard Randall (66) of Orange, CA.
  • Entity Used: Monte Vista Pharmacy.
  • Method: Billing for unnecessary or non-existent generic drugs during a Medi-Cal prior authorization suspension.
  • Financial Loss: Approximately $178 million stolen from taxpayers.
  • Timeline: May 2022 to April 2023.

This case serves as a stark reminder of the vulnerabilities that can emerge during the transition of large-scale government payment systems. As federal authorities continue their “war on fraud,” the prosecution of the Monte Vista Pharmacy scheme signals a zero-tolerance approach to the exploitation of taxpayer-funded healthcare programs.

About the author: Marcus Liu - Business Editor

MBA and ex‑B bureau chief specializing in global finance and fintech. Marcus speaks Mandarin, Japanese, and English, and has interviewed CEOs from the Fortune 50 to Y‑Combinator unicorns. Marcus Liu delivers sharp analysis on markets, startups, and corporate strategy for investors and entrepreneurs alike.